- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02065180
The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol Levels in Patients With Metabolic Syndrome
May 19, 2014 updated by: Veronique Verhoeven, Universiteit Antwerpen
The Effect of a Red Rice and Olive Extract Nutrition Supplement on Cholesterol
This randomised controlled trial studies the effect of a commercially available nutritional supplement on cholesterol levels in people with metabolic syndrome and elevated cholesterol levels.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
50
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Belgie
-
Antwerp, Belgie, Belgium, 2610
- University of Antwerp
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
metabolic syndrome according to ATPIII criteria 3 of the following:
- waist circumference >88cm (in females) or >102cm (in males)
- triglycerides >150mg/dl
- HDL <40 (50)mg/dl in males (females)
- blood pressure>130/85 or treatment for AHT
- glucose >110mg/dl
Exclusion Criteria:
- pregnancy
- treatment with cholesterol lowering drugs
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: commercially available nutrition supplement
this group receives a commercially available nutritional supplement for a period of 2 months
|
the food supplement contains red rice yeast and olive extract
|
Placebo Comparator: control group
this group receives a placebo for a period of 2 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
LDL level
Time Frame: 2 months
|
2 months
|
total cholesterol level
Time Frame: 2 months
|
2 months
|
triglyceride level
Time Frame: 2 months
|
2 months
|
HDL level
Time Frame: 2 months
|
2 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
OxLDL
Time Frame: 2 months
|
2 months
|
BMI
Time Frame: 2 months
|
2 months
|
malondialdehyde (MDA)
Time Frame: 2 months
|
2 months
|
8-OH-deoxyguanosine (8-OHdG)
Time Frame: 2 months
|
2 months
|
side effects
Time Frame: 2 months
|
2 months
|
waist circumference
Time Frame: 2 months
|
2 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Hermans N, Van der Auwera A, Breynaert A, Verlaet A, De Bruyne T, Van Gaal L, Pieters L, Verhoeven V. A red yeast rice-olive extract supplement reduces biomarkers of oxidative stress, OxLDL and Lp-PLA2, in subjects with metabolic syndrome: a randomised, double-blind, placebo-controlled trial. Trials. 2017 Jul 3;18(1):302. doi: 10.1186/s13063-017-2058-5.
- Verhoeven V, Van der Auwera A, Van Gaal L, Remmen R, Apers S, Stalpaert M, Wens J, Hermans N. Can red yeast rice and olive extract improve lipid profile and cardiovascular risk in metabolic syndrome?: A double blind, placebo controlled randomized trial. BMC Complement Altern Med. 2015 Mar 10;15:52. doi: 10.1186/s12906-015-0576-9.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2014
Primary Completion (Actual)
May 1, 2014
Study Completion (Actual)
May 1, 2014
Study Registration Dates
First Submitted
February 13, 2014
First Submitted That Met QC Criteria
February 14, 2014
First Posted (Estimate)
February 17, 2014
Study Record Updates
Last Update Posted (Estimate)
May 20, 2014
Last Update Submitted That Met QC Criteria
May 19, 2014
Last Verified
May 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- verhoevenhermans
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypercholesterolaemia
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedHypercholesterolaemiaFrance, Belgium, Netherlands
-
AstraZenecaTerminatedHypercholesterolaemiaUnited Kingdom
-
AmgenTerminatedPregnancy | HypercholesterolaemiaBelgium, Denmark, Italy, Czechia, United Kingdom, Australia, Austria, Greece, Switzerland, Netherlands, Spain, Sweden, Slovakia, Norway
-
AstraZenecaWithdrawnPrimary Hypercholesterolaemia
-
AkesoAD Pharmaceuticals Co., Ltd.Completed
-
GlaxoSmithKlineCompleted
-
AstraZenecaCompletedHypercholesterolaemiaBosnia and Herzegovina
-
AstraZenecaCompleted
-
AstraZenecaCompletedHypercholesterolaemiaGreece
Clinical Trials on placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States